Bleeding and thromboembolic risks of internal cardioversion for persistent atrial fibrillation.
Although internal cardioversion is an effective method for converting AF the thromboembolic risk and bleeding complication of this procedure remains unclear. Retrospective analysis of the thromboembolic events and bleeding complications was performed in 114 consecutive patients (mean age 63 +/- 10 years, 91 men) who underwent internal cardioversion for persistent AF (mean AF duration 31 +/- 42 months). All patients received therapeutic warfarin for 3 weeks prior to the procedure, which was then replaced by periprocedural heparin therapy during internal cardioversion. The mean INR value before the internal cardioversion was 1.3 +/- 0.2. A total of 992 R wave synchronized shocks were delivered (mean 8.7 shocks/patients) without ventricular proarrhythmia. Successful internal cardioversion of AF was achieved in 100 (88%) patients. Two (2%) patients developed major bleeding complications with pericardial effusion after the procedure. Both of them subsided with conservative treatment. Minor bleeding with wound hematoma occurred in 8 (7%) of 114 after the procedure. Overall, there was no significant difference in the risk of procedure related complication between the use of heparin infusion and subcutaneous LMWH injection (6/78 [13%] vs 3/36 [8%], P = 0.9). No thromboembolic event was observed after 4 weeks of follow-up. In conclusion, the risk of thromboembolism after discontinuation of anticoagulation before the procedure is low in patients with persistent AF underwent internal cardioversion. However, the use of periprocedural heparin therapy was associated with an increase risk of procedure related bleeding complications.
Tse
Hung-Fat
HF
Cardiology Division, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China. hftse@hkucc.hku.hk
Lau
Chu-Pak
CP
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000628:therapy*; D004554:Electric Countershock / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin